MX354302B - Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montaña por falta de oxigeno y presion de aire reducida. - Google Patents

Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montaña por falta de oxigeno y presion de aire reducida.

Info

Publication number
MX354302B
MX354302B MX2014015048A MX2014015048A MX354302B MX 354302 B MX354302 B MX 354302B MX 2014015048 A MX2014015048 A MX 2014015048A MX 2014015048 A MX2014015048 A MX 2014015048A MX 354302 B MX354302 B MX 354302B
Authority
MX
Mexico
Prior art keywords
sub
treatment
lack
oxygen
pharmaceutical composition
Prior art date
Application number
MX2014015048A
Other languages
English (en)
Spanish (es)
Other versions
MX2014015048A (es
Inventor
Fischer Bernhard
Lucas Rudolf
Fischer Hendrik
Original Assignee
Apeptico Forschung & Entwicklung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354302(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apeptico Forschung & Entwicklung Gmbh filed Critical Apeptico Forschung & Entwicklung Gmbh
Publication of MX2014015048A publication Critical patent/MX2014015048A/es
Publication of MX354302B publication Critical patent/MX354302B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2014015048A 2012-06-28 2013-06-19 Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montaña por falta de oxigeno y presion de aire reducida. MX354302B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12173983.3A EP2679239A1 (de) 2012-06-28 2012-06-28 Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
PCT/EP2013/062777 WO2014001177A1 (de) 2012-06-28 2013-06-19 Pharmazeutische zusammensetzung zur behandlung der durch sauerstoffarmut und verringerten luftdruck vermittelten pulmonalen form der höhenkrankheit

Publications (2)

Publication Number Publication Date
MX2014015048A MX2014015048A (es) 2015-06-05
MX354302B true MX354302B (es) 2018-02-23

Family

ID=48672620

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015048A MX354302B (es) 2012-06-28 2013-06-19 Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montaña por falta de oxigeno y presion de aire reducida.

Country Status (14)

Country Link
US (2) US9802985B2 (enExample)
EP (2) EP2679239A1 (enExample)
JP (1) JP6113277B2 (enExample)
KR (1) KR102010793B1 (enExample)
CN (1) CN104427993B (enExample)
AP (1) AP2014008162A0 (enExample)
AU (1) AU2013283563B2 (enExample)
CA (1) CA2875749C (enExample)
EA (1) EA030384B1 (enExample)
ES (1) ES2602197T3 (enExample)
IN (1) IN2015DN00585A (enExample)
MX (1) MX354302B (enExample)
PE (1) PE20150198A1 (enExample)
WO (1) WO2014001177A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939635A1 (en) * 2014-03-04 2015-09-11 Apeptico Forschung Und Entwicklung Gmbh Attenuation of intrapulmonary inflammation
ES2665180T3 (es) * 2014-03-18 2018-04-24 Apeptico Forschung Und Entwicklung Gmbh Medicamento de péptido en forma de polvo seco
EP3365275A4 (en) 2015-08-25 2019-06-26 Bar-Ilan University ASYMMETRIC ELECTROCHEMICAL CELL DEVICE AND METHOD OF OPERATING THE SAME
US11439869B2 (en) 2017-05-19 2022-09-13 Trudell Medical International Positive expiratory pressure device
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
WO2021087037A1 (en) * 2019-10-29 2021-05-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Lung-specific targeting-peptide (ltp), compositions, and uses thereof
IL294894A (en) 2020-05-08 2022-09-01 Apeptico Forschung & Entwicklung Gmbh A peptide for the prevention or treatment of covid-19
KR20250164550A (ko) 2024-05-16 2025-11-25 장태현 고산병 예방을 위한 입술용 화장료 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5891679A (en) 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
CZ302862B6 (cs) * 1998-08-14 2011-12-21 Lécivo na lécení otoku
JP5108515B2 (ja) * 2004-08-06 2012-12-26 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺サーファクタント及びｔｎｆ由来ペプチドを含有する組成物
EP2009023A1 (en) 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506150B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
MX2011009251A (es) * 2009-03-04 2011-11-18 Mannkind Corp Sistema mejorado de suministro de farmaco en polvo seco.
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase

Also Published As

Publication number Publication date
KR20150037815A (ko) 2015-04-08
CA2875749C (en) 2019-02-26
KR102010793B1 (ko) 2019-08-14
US9802985B2 (en) 2017-10-31
EP2679239A1 (de) 2014-01-01
CA2875749A1 (en) 2014-01-03
EA030384B1 (ru) 2018-07-31
US20150225460A1 (en) 2015-08-13
WO2014001177A1 (de) 2014-01-03
EP2866824A1 (de) 2015-05-06
AP2014008162A0 (en) 2014-12-31
ES2602197T3 (es) 2017-02-20
CN104427993A (zh) 2015-03-18
CN104427993B (zh) 2017-03-08
AU2013283563A1 (en) 2015-01-15
IN2015DN00585A (enExample) 2015-06-26
AU2013283563B2 (en) 2017-06-08
MX2014015048A (es) 2015-06-05
US20190211061A1 (en) 2019-07-11
EP2866824B1 (de) 2016-08-10
JP6113277B2 (ja) 2017-04-12
JP2015526399A (ja) 2015-09-10
PE20150198A1 (es) 2015-02-19
EA201500061A1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
IN2015DN00585A (enExample)
MX341324B (es) Polipeptidos.
MX2013001677A (es) Formulaciones estables de linaclotida.
NZ601374A (en) Stabilized antibody-containing liquid formulations
MX356671B (es) Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa.
EP4234698A3 (en) Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
WO2010085700A3 (en) Treatment for obesity
GB201313381D0 (en) Fluorocarbon-linked peptide formulation
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
MX2012008413A (es) Composicion novedosa de retigabina.
IN2014DN06920A (enExample)
PH12012501340A1 (en) Composition for improving brain function and method for improving brain function
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
TN2012000507A1 (en) Enteric tablet
WO2013021284A3 (en) Anti-il-6 vaccine composition
NZ596501A (en) Casb7439 constructs
WO2012019086A3 (en) Inhibition of lar phosphatase to enhance therapeutic angiogenesis
WO2009158238A3 (en) Fibroblast growth factor (fgf) analogs and uses thereof
NZ732301A (en) Peptide compound, preparation method therefor, and application thereof
PH12013500945A1 (en) Crystalline forms of an alkoxymidazol-1-ylmethyl-biphenyl carboxylic acid
WO2010118286A3 (en) Benzimidazole modulators of h1 receptor and/or ns4b protein activity
WO2010041827A3 (en) NF-κB INHIBITOR CONTAINING ARH1 PROTEIN OR GENE ENCODING THE SAME
WO2012102625A3 (en) Therapeutic composition
GB2522163A (en) Fat loss composition
WO2012064306A3 (en) Effervescent formulations of rosuvastatin

Legal Events

Date Code Title Description
FG Grant or registration